de antidiabéticos orales: los inhibidores del co-transpor- tador de sodio y glucosa 2 (SGLT2). La dapagliflozina actúa como un inhibidor selectivo, reversible y. Aportaciones respecto a las otras familias de antidiabéticos orales. Update on the latest family of oral drugs marketed for the treatment of type 2 diabetes: DPP- 4. Discover ideas about Diabetes. Clasificación de los antidiabéticos orales. DiabetesPharmacologyNursingChemistrySurgeryWellnessHome Remedies Medicinal.
|Published (Last):||19 November 2014|
|PDF File Size:||4.25 Mb|
|ePub File Size:||7.34 Mb|
|Price:||Free* [*Free Regsitration Required]|
The recent introduction of new drugs in the therapeutic arsenal for the management of hyperglycemia in type 2 diabetes has opened up new perspectives and raised hope for improved metabolic control in these patients. DPP-4 inhibitors are a family of drugs whose action is mediated by the incretin hormones, in particular GLP This hormone is involved in the control of glucose homeostasis, as it stimulates insulin secretion in response to food intake and halts glucagon production.
This effect, which is altered in patients with type 2 diabetes, can be improved by administering this group of drugs. The available evidence suggests that the efficacy, tolerability, safety, low drop-out rate and limited effects on weight, together with the low risk of hypoglycemic episodes, could place this group of drugs high on the treatment list in patients with type 2 diabetes.
Incretin therapy provides an alternative to currently available glucose-lowering drugs for type 2 diabetes with good efficacy and a favorable antiidiabeticos on weight. In the studies performed to date, DPP-4 inhibitors seem safe. However, these agents must continue to be evaluated in long-term studies performed in oralse practice to ensure their effectiveness and safety profile, as well as to determine their precise role among all the currently available options in the treatment of type 2 diabetes.
Update on the latest family of oral drugs marketed for the treatment of type 2 diabetes: Contributions with respect to other families of oral antidiabetic agents. However, these antidiabetixos must continue to be evaluated in long-term studies performed in clinical practice to ensure their effectiveness and safety profile, as well as to determine their precise role among all the currently available options in the treatment of type 2 diabetes.
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes UKPDS BMJ,pp. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med,pp.
antidiaebticos Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. Ann Intern Med,pp. Diabetes Metab Res Rev, 26pp. Lancet,pp. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function.
Am J Med,pp. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in oralex treatment of type 2 diabetes mellitus. Curr Opin Pharmacol, 4pp. Effect of Noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.
ANTIDIABETICOS ORALES PDF
antidiabeticis JAMA,pp. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: Pharmacotherapy, 26pp. Dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Diabetes, 54pp.
Efficacy and safety of incretin therapy in type 2 diabetes. Systematic review and meta-analysis. Inhibition of DPP 4: Curr Med Res Opin, 23pp. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.
Postgrad Med,pp. Mekki, Alogliptin Study Group.
Efficacy and safety of the dipeptydil peptidase-4 inhibitor alogliptin in patients antixiabeticos type 2 diabetes mellitus inadequately controlled by glyburide monotherapy. Diabetes Obes Metab, 11pp. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: Int J Clin Pract, 63pp. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: Curr Med Res Opin, 25pp.
Ravichandran, Saxagliptin Study Group. Antidiabetivos efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care, 32pp.
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab, 94pp. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients antidiabeticow type 2 dia betes: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Diabetes Care, 29pp. Stein, Sitagliptin Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: Clin Ther, 28pp.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab, 9pp. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Diabetes Care, 30pp. Lixisenatida en pacientes con diabetes tipo 2 y obesidad Si continua navegando, consideramos que acepta su uso.
ANTIDIABETICOS ORALES PDF
To lrales our services and products, we use “cookies” own or third parties authorized to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.
Se continuar a navegar, consideramos que aceita o seu uso. Are you a health professional able to prescribe or dispense drugs?